Відмінності між версіями «Le disease in peripheral blood or bone marrow even when»
м |
м |
||
| Рядок 1: | Рядок 1: | ||
| − | In | + | In line with D ner's hierarchical model, 17/221 (8 ) and 40/221 (18 ) individuals had 17p deletion and 11q deletion, respectively.Le disease in peripheral blood or bone marrow even when extremely sensitive immunophenotypic or molecular techniques are made use of to look for residual illness. These sufferers are regarded as to have accomplished a minimal residual disease (MRD) damaging status.17-20 Several phase II trials have demonstrated that individuals attaining MRD negativity have a signif-icantly longer survival than people that remain MRD positive, and this really is true for individuals treated with conventional chemotherapy,21,22 monoclonal antibodies,23 chemoimmunotherapy,24 or stem cell transplantation.25,26 Moreover, a phase III trial performed by the German CLL Study Group (GCLLSG) lately revealed that individuals acquiring MRD negativity had drastically longer progression-free and overall survivals, irrespectively in the therapy received.18 Regrettably, however, a few of these research had been flawed by inappropriate statistical analysis, particularly the measurement of time-to-event outcomes from remedy initiation.27 Additionally, there are numerous caveats to the use of MRD analysis in patients with CLL.28 First, CLL remains incurable and a minimum of 30 of sufferers who achieve MRD negativity following front-line therapy with fludarabine-cyclophosphamide (FC) or rituximab-FC at some point experience a disease relapse within 5 years.18 Secondly, unlike the situation in acute promyelocytic leukemia or chronic myeloid leukemia,29,30 there's no formal proof of a therapeutic benefit of re-treatment upon documentation of MRD positivity immediately after an initial MRD-negative response in comparison with treatment at the time of clinical relapse. In reality, extremely few studies have demonstrated a clear advantage from MRD eradication or consolidation therapy in CLL,31,32 and some from the tactics tested, while powerful, resulted in considerable toxicity.33-35 Thirdly, it may very well be argued that MRD assessment is merely a surrogate for evalution of other adverse prognostic markers considering the fact that, for example, sufferers with a 17p014 Ferrata Storti Foundation. This really is an open-access paper. doi:10.3324/haematol.2013.099796 The on-line version of this article features a Supplementary Appendix. Manuscript received on October 17, 2013. Manuscript accepted on December 31, 2013. Correspondence: jdelgado@clinic.ub.eshaematologica | 2014; 99(5)R. Santacruz et al.deletion possess a greater probability of remaining MRD-positive immediately after therapy when compared with sufferers without the need of this chromosome abnormality.18 For all these factors, current suggestions for the management of sufferers with CLL propose MRD assessment only within clinical trials with "curative intention".36 With all this facts in thoughts, we retrospectively evaluated the effect of MRD around the outcome of individuals with CLL receiving any front-line therapy in the context of an incredibly detailed prognostic evaluation, which includes lately described recurrent gene mutations.survival and general survival had been calculated employing a landmark analysis. All calculations were performed [http://mainearms.com/members/nerveguide65/activity/1671141/ Rom the food supply. Sources of preformed vitamin D] utilizing either SPSS, version 18.0, or R, version three.0.1. Two-sided P values 0.05 had been considered statistically substantial. A detailed explanation in the statistical approaches is obtainable inside the On the internet Supplement.Benefits Baseline characteristicsThe median age with the whole cohort was 58 years (range, 27-93 years), along with the percentage of individuals older than 70 years was 22 . |
Версія за 10:54, 1 лютого 2018
In line with D ner's hierarchical model, 17/221 (8 ) and 40/221 (18 ) individuals had 17p deletion and 11q deletion, respectively.Le disease in peripheral blood or bone marrow even when extremely sensitive immunophenotypic or molecular techniques are made use of to look for residual illness. These sufferers are regarded as to have accomplished a minimal residual disease (MRD) damaging status.17-20 Several phase II trials have demonstrated that individuals attaining MRD negativity have a signif-icantly longer survival than people that remain MRD positive, and this really is true for individuals treated with conventional chemotherapy,21,22 monoclonal antibodies,23 chemoimmunotherapy,24 or stem cell transplantation.25,26 Moreover, a phase III trial performed by the German CLL Study Group (GCLLSG) lately revealed that individuals acquiring MRD negativity had drastically longer progression-free and overall survivals, irrespectively in the therapy received.18 Regrettably, however, a few of these research had been flawed by inappropriate statistical analysis, particularly the measurement of time-to-event outcomes from remedy initiation.27 Additionally, there are numerous caveats to the use of MRD analysis in patients with CLL.28 First, CLL remains incurable and a minimum of 30 of sufferers who achieve MRD negativity following front-line therapy with fludarabine-cyclophosphamide (FC) or rituximab-FC at some point experience a disease relapse within 5 years.18 Secondly, unlike the situation in acute promyelocytic leukemia or chronic myeloid leukemia,29,30 there's no formal proof of a therapeutic benefit of re-treatment upon documentation of MRD positivity immediately after an initial MRD-negative response in comparison with treatment at the time of clinical relapse. In reality, extremely few studies have demonstrated a clear advantage from MRD eradication or consolidation therapy in CLL,31,32 and some from the tactics tested, while powerful, resulted in considerable toxicity.33-35 Thirdly, it may very well be argued that MRD assessment is merely a surrogate for evalution of other adverse prognostic markers considering the fact that, for example, sufferers with a 17p014 Ferrata Storti Foundation. This really is an open-access paper. doi:10.3324/haematol.2013.099796 The on-line version of this article features a Supplementary Appendix. Manuscript received on October 17, 2013. Manuscript accepted on December 31, 2013. Correspondence: jdelgado@clinic.ub.eshaematologica | 2014; 99(5)R. Santacruz et al.deletion possess a greater probability of remaining MRD-positive immediately after therapy when compared with sufferers without the need of this chromosome abnormality.18 For all these factors, current suggestions for the management of sufferers with CLL propose MRD assessment only within clinical trials with "curative intention".36 With all this facts in thoughts, we retrospectively evaluated the effect of MRD around the outcome of individuals with CLL receiving any front-line therapy in the context of an incredibly detailed prognostic evaluation, which includes lately described recurrent gene mutations.survival and general survival had been calculated employing a landmark analysis. All calculations were performed Rom the food supply. Sources of preformed vitamin D utilizing either SPSS, version 18.0, or R, version three.0.1. Two-sided P values 0.05 had been considered statistically substantial. A detailed explanation in the statistical approaches is obtainable inside the On the internet Supplement.Benefits Baseline characteristicsThe median age with the whole cohort was 58 years (range, 27-93 years), along with the percentage of individuals older than 70 years was 22 .
